You just read:

Daiichi Sankyo's Once-Daily LIXIANA® (edoxaban) Approved in the EU for Stroke Prevention in Nonvalvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent DVT and PE

News provided by

Daiichi Sankyo Europe GmbH

25 Jun, 2015, 08:00 BST